Teva To Return With Vincristine In US
Responding To Market Shortages
Amid market shortages of the pediatric cancer treatment as Pfizer struggles to meet demand, Teva has decided to resume producing vincristine in the US and plans to start shipments next year.
You may also be interested in...
The AAM has commended the FDA’s efforts on identifying the root causes of drug shortages in 2019 and has committed to work with the agency in pursuit of a “healthy, sustainable market for safe, effective and affordable medicines for patients.”
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.